Multifactorial chylomicronemia syndrome.

Journal

Current opinion in endocrinology, diabetes, and obesity

ISSN: 1752-2978

Titre abrégé: Curr Opin Endocrinol Diabetes Obes

Pays: England

ID NLM: 101308636

Informations de publication

Date de publication:
24 Nov 2023

Historique:

medline: 23 11 2023

pubmed: 23 11 2023

entrez: 23 11 2023

Statut: aheadofprint

Résumé

The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment. There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment. New approaches to triglyceride lowering will help reduce the risk of pancreatitis, the major complication of MFCS. MCSF is a condition in which plasma triglyceride levels are severely elevated, usually to due exacerbation of common genetic forms of hypertriglyceridemia by secondary causes of hypertriglyceridemia and/or triglyceride-raising drugs. Triglyceride-induced pancreatitis can be prevented by markedly reducing triglyceride levels by treating secondary causes and/or eliminating of triglyceride-raising drugs, and by using triglyceride-lowering drugs, especially fibrates. MFCS also increases cardiovascular disease risk, for which lifestyle measures and drugs are required.

Identifiants

DOI: 10.1097/MED.0000000000000846 PMID: 37994661

pubmed: 37994661

doi: 10.1097/MED.0000000000000846

pii: 01266029-990000000-00081

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol 2020; 11:455.

Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2:655–666.

Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol 2020; 11:593931.

Chen YQ, Pottanat TG, Zhen EY, et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res 2021; 62:100068.

Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973; 52:1578–1585.

Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med 2019; 170:626–634.

Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134–2139.

Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf) 2009; 195:13–28.

Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology, and prognosis. Curr Gastroenterol Rep 2009; 11:97–103.

Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med 2014; 25:689–694.

Wang Q, Wang G, Qiu Z, et al. Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol 2017; 51:586–593.

Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J 2020; 41:99–109c.

Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335:848–854.

Chait A, Robertson HT, Brunzell JD. Chylomicronemia syndrome in diabetes mellitus. Diabetes Care 1981; 4:343–348.

Maltais M, Brisson D, Gaudet D. Non-alcoholic fatty liver in patients with chylomicronemia. J Clin Med 2021; 10:669.

De Villers-Lacasse A, Paquette M, Baass A, Bernard S. Nonalcoholic fatty liver disease in patients with chylomicronemia syndromes. J Clin Lipidol 2023; 17:475–482.

Brahm AJ, Hegele RA. Chylomicronaemia-current diagnosis and future therapies. Nat Rev Endocrinol 2015; 11:352–362.

Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res 2020; 61:1365–1376.

Blom DJ, O’Dea L, Digenio A, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol 2018; 12:1234–1243. e5.

O’Dea LSL, MacDougall J, Alexander VJ, et al. Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles. J Endocr Soc 2019; 3:2397–2410.

Tremblay K, Gaudet D, Khoury E, Brisson D. Dissection of clinical and gene expression signatures of familial versus multifactorial chylomicronemia. J Endocr Soc 2020; 4:bvaa056.

Belhassen M, Van Ganse E, Nolin M, et al. 10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes. J Clin Endocrinol Metab 2021; 106:e1332–e1342.

Chaudhry R, Viljoen A, Wierzbicki AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol 2018; 11:589–598.

Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371:2200–2206.

Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis 2019; 283:137–142.

D’Erasmo L, Di Costanzo A, Cassandra F, et al. Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes. Arterioscler Thromb Vasc Biol 2019; 39:2531–2541.

Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol 2018; 12:920–927. e4.

Rioja J, Ariza MJ, Garcia-Casares N, et al. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic. Eur J Clin Invest 2020; 50:e13345.

Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol 2019; 13:80–88.

Berberich AJ, Hegele RA. Genetic testing in dyslipidaemia: an approach based on clinical experience. Best Pract Res Clin Endocrinol Metab 2023; 37:101720.

Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an ‘FCS score’. Atherosclerosis 2018; 275:265–272.

Moulin P, Dufour R, Averna M, et al. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): establishment of an FCS clinical diagnostic score. Data Brief 2018; 21:1334–1336.

Hegele RA. Is genetic testing in hypertriglyceridemia useful? Arterioscler Thromb Vasc Biol 2022; 42:1468–1470.

Chait A, Subramanian S. Hypertriglyceridemia: pathophysiology, role of genetics, consequences, and treatment. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth, MA; 2000.

Capell WH, Eckel RH. Treatment of hypertriglyceridemia. Curr Diab Rep 2006; 6:230–240.

Fantino M, Paquette M, Blais C, et al. Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study. Nutr Res 2022; 101:43–52.

O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392:637–649.

Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 1983; 32:209–214.

Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. Endocr Pract 2018; 24:756–763.

Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015; 373:438–447.

Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol 2021; 32:335–341.

Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med 2023; 29:729–737.

Watts GF, Schwabe C, Scott R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med 2023; 29:2216–2223.

Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf 2015; 14:1481–1493.